Filana Therapeutics, Inc. (FLNA)
NASDAQ: FLNA · Real-Time Price · USD
0.9610
+0.0185 (1.96%)
At close: Aug 21, 2026, 4:00 PM EDT
0.9542
-0.0068 (-0.71%)
After-hours: Aug 21, 2026, 7:59 PM EDT

Filana Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cost of Revenue
15.6626.5969.6489.4268.0324.81
Gross Profit
-15.66-26.59-69.64-89.42-68.03-24.81
Selling, General & Admin
-4.9833.581.7116.6311.998.06
Operating Expenses
-4.9833.581.7116.6311.998.06
Operating Income
-10.67-60.09-151.35-106.06-80.02-32.87
Interest & Investment Income
3.684.628.517.832.780.05
Other Non Operating Income (Expenses)
0.02-0.2108.590.9110.43
EBT Excluding Unusual Items
-6.98-55.67-34.24-97.32-76.25-32.39
Legal Settlements
-35.3-35.3----
Pretax Income
-42.28-90.97-24.34-97.22-76.25-32.39
Net Income
-42.28-90.97-24.34-97.22-76.25-32.39
Net Income to Common
-42.28-90.97-24.34-97.22-76.25-32.39
Net Income Growth
------
Shares Outstanding (Basic)
484846424039
Shares Outstanding (Diluted)
484847424039
Shares Change
0.24%3.63%11.14%4.30%2.02%50.95%
EPS (Basic)
-0.88-1.88-0.53-2.32-1.90-0.82
EPS (Diluted)
-0.88-1.88-1.46-2.32-1.90-0.82
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-29.3-32.83-117.03-82.44-80.23-52.41
Free Cash Flow Per Share
-0.61-0.68-2.51-1.97-2.00-1.33
EBITDA
-9.69-59.15-150.21-104.53-78.72-32.33
D&A For EBITDA
0.990.941.131.531.30.53
EBIT
-10.67-60.09-151.35-106.06-80.02-32.87
SEC Filings: 10-K · 10-Q